Search

Belhaven BioPharma Intranasal Epinephrine Delivery Device Patent

Belhaven BioPharma Inc. received US Patent 12605517B1 on April 21, 2026, titled 'Compositions, devices, and methods for intranasal delivery of dry powder epinephrine.' The patent contains 15 claims and names Scott Lyman and Brian Taubenheim as inventors. The patented compositions include epinephrine with a stabilizing agent (citric acid or salt) and carrier for intranasal dry powder delivery. The patent is assigned under CPC classifications A61M 15/08, A61M 11/003, A61K 9/0043, and A61K 31/137. Belhaven BioPharma now holds enforceable intellectual property rights to this intranasal epinephrine formulation in the United States. Competitors developing similar intranasal epinephrine delivery systems for anaphylaxis or respiratory conditions should conduct Freedom to Operate analyses to assess potential infringement exposure.